Rabbit Recombinant Monoclonal Bim antibody - conjugated to PE.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
Induces apoptosis and anoikis. Isoform BimL is more potent than isoform BimEL. Isoform Bim-alpha1, isoform Bim-alpha2 and isoform Bim-alpha3 induce apoptosis, although less potent than isoform BimEL, isoform BimL and isoform BimS. Isoform Bim-gamma induces apoptosis. Isoform Bim-alpha3 induces apoptosis possibly through a caspase-mediated pathway. Isoform BimAC and isoform BimABC lack the ability to induce apoptosis.
BIM, BCL2L11, Bcl-2-like protein 11, Bcl2-L-11, Bcl2-interacting mediator of cell death
Rabbit Recombinant Monoclonal Bim antibody - conjugated to PE.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Based on the sequence homology of the immunogen, this antibody is likely to detect all Bim isoforms.
This conjugated primary antibody is “made to order” and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link® conjugation technology, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Bim also known as Bcl-2-interacting mediator of cell death is an important pro-apoptotic protein within the Bcl-2 family. It has a molecular weight of approximately 23 kDa. Bim is expressed in various tissues including the immune system nervous system and lymphoid tissues. It exists in multiple isoforms such as BimEL BimL and BimS due to alternative splicing. Bim's interaction with cellular membranes allows it to regulate apoptotic processes through mitochondrial pathways effectively.
Bim regulates apoptosis by binding to pro-survival proteins like Bcl-2 and Bcl-xL releasing pro-apoptotic factors from mitochondria and activating caspases. Bim acts as part of the apoptosome complex and influences cell death regulation significantly. By promoting cytochrome c release from mitochondria Bim initiates a cascade of events leading to cell apoptosis. This regulation is vital in maintaining the balance between cell survival and death necessary for normal development and tissue homeostasis.
Bim plays a critical role in the intrinsic apoptotic pathway. This pathway involves mitochondrial outer membrane permeabilization where Bim interacts with several Bcl-2 family proteins such as Bax and Bak to induce apoptosis. The modulation of Bim expression and activity is influenced by growth factor signaling pathways such as the PI3K-Akt pathway which affects Bim phosphorylation leading to its inactivation and subsequent degradation. Therefore Bim acts as an important node linking survival signals and apoptotic machinery.
Bim dysregulation has been implicated in conditions like cancer and autoimmune diseases. In certain cancers reduced Bim expression can result in unchecked cell proliferation and resistance to apoptosis. Conversely in autoimmune disorders overactivity of Bim may lead to excessive immune cell apoptosis contributing to disease pathogenesis. Bim's interactions with proteins like Bcl-2 and Bcl-xL are significant in cancer therapy as targeting these interactions can help overcome resistance to apoptosis in cancer cells improving treatment outcomes.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com